Browse SLC5A5

Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00474 Sodium
Function

Mediates iodide uptake in the thyroid gland.

> Gene Ontology
 
Biological Process GO:0006575 cellular modified amino acid metabolic process
GO:0006590 thyroid hormone generation
GO:0006814 sodium ion transport
GO:0006820 anion transport
GO:0010817 regulation of hormone levels
GO:0014074 response to purine-containing compound
GO:0015672 monovalent inorganic cation transport
GO:0015698 inorganic anion transport
GO:0015705 iodide transport
GO:0018958 phenol-containing compound metabolic process
GO:0034698 response to gonadotropin
GO:0035725 sodium ion transmembrane transport
GO:0042403 thyroid hormone metabolic process
GO:0042445 hormone metabolic process
GO:0046683 response to organophosphorus
GO:0051591 response to cAMP
GO:0071320 cellular response to cAMP
GO:0071371 cellular response to gonadotropin stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0098656 anion transmembrane transport
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0008507 sodium:iodide symporter activity
GO:0008509 anion transmembrane transporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015111 iodide transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015296 anion:cation symporter activity
GO:0015370 solute:sodium symporter activity
GO:0015373 monovalent anion:sodium symporter activity
GO:0022804 active transmembrane transporter activity
GO:0022853 active ion transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04918 Thyroid hormone synthesis
Reactome R-HSA-209776: Amine-derived hormones
R-HSA-425374: Amino acid and oligopeptide SLC transporters
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-428643: Organic anion transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-209968: Thyroxine biosynthesis
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC5A5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SLC5A5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21608083Breast CarcinomaPromote immunityTumor bearing animals received an intravenous or intratumoral injection of NIS expressing MSCs (MSC-NIS), followed by (99m) Technetium pertechnetate imaging 3-14 days later using a BazookaSPECT γ-camera. Based on imaging/biodistribution data, animals received a therapeutic dose of (131) I 14 days after MSC-NIS injection. This resulted in a significant reduction in tumor growth (mean ± SEM, 236 ± 62 mm(3) vs. 665 ± 204 mm(3) in controls).
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC5A5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC5A5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1820.724
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0580.952
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4910.682
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.250.115
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1980.457
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1810.462
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3630.413
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1380.686
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC5A5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC5A5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC5A5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC5A5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC5A5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC5A5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC5A5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC5A5
Namesolute carrier family 5 (sodium/iodide cotransporter), member 5
Aliases NIS; solute carrier family 5 (sodium iodide symporter), member 5; TDH1; Na(+)/I(-) cotransporter; Na(+)/I(-) ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC5A5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.